GlassScriptPhysician profile
Mansoor A Khan
NPI 1497937890
$4,512.40
in general payments reported to CMS, 2019-2025
18 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $648 · 2021: $319 · 2022: $279 · 2023: $1,305 · 2024: $1,017 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,582 · Travel and Lodging: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.76 |
| Travel and Lodging | $1,220.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,452.14 | 2019-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $882.71 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Ascenda |
| Medtronic USA, INC. | $523.11 | 2019-2020 | |
| Grt US Holding, INC. | $112.63 | 2020-2021 | |
| Vertos Medical, INC. | $101.72 | 2019-2020 | |
| Stryker Corporation | $101.53 | 2024 | Mild Device Kit |
| Flowonix Medical Incorporated | $62.33 | 2020 | |
| Si-Bone, INC. | $58.58 | 2019-2024 | |
| Biotronik Nro, INC. | $42.96 | 2025 | Prospera |
| Fidia Pharma USA INC. | $34.14 | 2019 | |
| Nevro Corp. | $33.50 | 2019-2021 | |
| Valinor Pharma, LLC | $19.32 | 2025 | Movantik |
| Tersera Therapeutics LLC | $18.91 | 2023 | Prialt |
| Horizon Therapeutics Plc | $16.31 | 2019 | |
| Spinal Simplicity, LLC | $15.66 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amniox Medical, INC. | $13.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.12 | 2019 | |
| Daiichi Sankyo INC. | $11.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansoor Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.